Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501438 | 0.84 | CHRM2 (0.31) | CHRM2CHRM1CHRM3 | |
| SCHEMBL1769389 | 0.83 | GPR119 (0.37) | KDM4E | |
| SCHEMBL1150307 | 0.83 | GPR119 (0.37) | KDM4E | |
| SCHEMBL29624640 | 0.79 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL18987136 | 0.79 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL4035983 | 0.79 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL4035987 | 0.79 | CHRM2 (0.41) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL8972514 | 0.78 | CHRM2 (0.33) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL29261319 | 0.77 | CHRM2 (0.39) | CHRM2CHRM1CHRM3KDM4EMAPT | |
| SCHEMBL29261316 | 0.77 | CHRM2 (0.39) | CHRM2CHRM1CHRM3KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2195328-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Incorporated (US) | 2010-06-16 | — | — | EP | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| WO-2009023193-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-1004578-B1 | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1004578-A2 | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | CHRM2 35/4885CHRM1 63/4885CHRM3 29/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CHRM2 35/4885CHRM1 63/4885CHRM3 29/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CHRM2 35/4885CHRM1 63/4885CHRM3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.